Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy

Chronic myeloid leukemia (CML) with T315I mutation has been reported to have poor prognosis. We analyzed 27 patients with T315I, including 20 who developed T315I after imatinib failure (representing 11% of 186 patients with imatinib failure), and 7 of 23 who developed new mutations after second tyro...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Jabbour, Elias, Kantarjian, Hagop, Jones, Dan, Breeden, Megan, Garcia-Manero, Guillermo, O'Brien, Susan, Ravandi, Farhad, Borthakur, Gautam, Cortes, Jorge
Format: Artigo
Jezik:Inglês
Izdano: American Society of Hematology 2008
Teme:
Clinical Trials and Observations
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4081375/
https://ncbi.nlm.nih.gov/pubmed/18403620
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2007-11-123950
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items